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Abstract
Background: Despite consensus criteria, diagnosing acute lung injury, or its more severe form
acute respiratory distress syndrome (ALI/ARDS) remains challenging. Adding objective measures,
such as plasma levels of biological markers could facilitate recognition of ALI/ARDS. This study was
designed to assess and compare the diagnostic accuracy of biological markers for ALI/ARDS with
ventilator-associated pneumonia (VAP).
Methods: We performed serial measurements of Clara cell protein (CC16), soluble receptor for
advanced glycation end products (sRAGE), surfactant protein D (SP-D) and Krebs von den Lungen
(KL-6) in plasma of patients with VAP and mechanically ventilated control patients without VAP.
ALI/ARDS was diagnosed using the criteria of the North-American European consensus
conference.
Results: Thirty-seven patients were enrolled - 22 patients with VAP and 15 control patients. Ten
patients with pneumonia met the ALI/ARDS consensus criteria. Control patients never met these
criteria. Plasma CC16 had a good diagnostic capacity for ALI/ARDS as shown by the receiver
operating characteristic curve with an area under the curve of 0.91 (95% confidence interval (CI)
0.79 - 1.00; p < 0.001). Identification of ALI/ARDS patients by sudden increases in plasma CC16 of
30% or more yielded a sensitivity of 90% and a specificity of 92%. Of note, levels of CC16 increased
2 days before ALI/ARDS diagnosis. A cut-off level of 50 ng/ml SP-D yielded a specificity of 100%
while the sensitivity was 70%. The area under the curve for SP-D was 0.80 (95% CI 0.58 - 1.00; p
= 0.02). The diagnostic accuracies of KL-6 and sRAGE were low.
Conclusion: Plasma CC16 seems a potential biological marker for ALI/ARDS in patients with VAP.
Plasma levels of sRAGE, SP-D and KL-6 have limited discriminative power for diagnosing ALI/ARDS
in VAP.
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Background
Intubated and mechanically ventilated patients are at risk
for ventilator-associated pneumonia (VAP) [1]. Develop-
ment of acute lung injury (ALI) or its more severe form,
acute respiratory distress syndrome (ARDS) decreases the
chance of survival [2]. Early and adequate recognition of
ALI/ARDS is mandatory for intensive care physicians to
take sufficient action at the right time (e.g., the use of so-
called lung-protective mechanical ventilation [3], and
refinement of fluid management [4]). In today's intensive
care practice, ALI/ARDS is diagnosed by means of the
North-American European consensus conference
(NAECC) criteria [5]. However, diagnosing ALI/ARDS
remains challenging, at least in part due to personal inter-
pretation of these criteria [6]. In addition, use of higher
levels of positive end-expiratory pressure can improve
both the PaO2/FiO2-ratio and abnormalities on chest radi-
ographs to the extent that the patients no longer fulfill the
ALI/ARDS criteria (per definition) [7].
Biological markers may facilitate the recognition of ALI/
ARDS as they are objectively obtained and not subject to
personal interpretation. Many proteins involved in the
pathophysiology of ALI/ARDS have been suggested as
biological markers, including Clara cell protein (CC16)
[8], soluble receptor for advanced glycation end products
(sRAGE) [9], surfactant protein D (SP-D) [10] and Krebs
von den Lungen (KL)-6) [11]. CC16 is a small 16 kDa pro-
tein and is the main secretion product of Clara cells
located in the terminal airways [8]. sRAGE is a membrane-
bound protein that is strongly expressed by alveolar type I
cells [12]. SP-D is produced and secreted by alveolar type
II cells as well as Clara cells [13] and KL-6 is expressed by
type II cells in the lungs [14]. During pulmonary inflam-
mation, proteins bound to the alveolar epithelial mem-
brane (sRAGE and KL-6) are released in the alveolar space.
It is suggested that the membrane-bound proteins are sep-
arated from the membrane as a result of cell injury and
accumulate in the epithelial lining fluid. In line with this,
increased concentrations of KL-6 and sRAGE in epithelial
lining fluid of patients with ALI/ARDS have been
observed [9,11]. Furthermore, it is postulated that due to
increased permeability of the alveolocapillary membrane
these proteins and the secretory proteins CC16 and SP-D,
leak into the circulation. Indeed, increased plasma levels
of CC16, surfactant proteins, sRAGE and KL-6 have been
reported in patients with ALI/ARDS [9-11,15,16]. Moreo-
ver, plasma CC16 and SP-D levels have prognostic signif-
icance in patients with ALI/ARDS [15,16].
While many studies have focused on the prognostic value
of these proteins, the diagnostic value for ALI/ARDS has
not been investigated in critically ill patients at risk for
ALI/ARDS. We measured plasma levels of CC16, sRAGE,
SP-D, and KL-6 in intubated and mechanically ventilated
patients who were at risk for VAP and determined the
diagnostic accuracy of these proteins for the diagnosis of
ALI/ARDS in patients with VAP. The present study was pri-
marily designed to study CC16 and SP-D. After recent
reports on sRAGE and KL-6 as new potential markers for
ALI/ARDS [9,11] we decided to compare these with CC16
and SP-D. Part of the results of this study have been previ-
ously reported in the form of an abstract [17].
Methods
Study population
A single-center retrospective observational study was con-
ducted between 2001 and 2003 in the intensive care unit
of the John Radcliffe Hospital in Oxford, UK. Although
the study protocol was performed prospectively, the
present study on diagnostic accuracy was designed retro-
spectively. Patients ≥18 yrs of age who were intubated and
mechanically ventilated with an expected duration of
mechanical ventilation of ≥72 hrs were included in the
study. Immunocompromised patients were excluded. In
view of the observational nature of the study, the rela-
tively small volumes of blood sampled (5 ml on alternate
days, see further), and the impossibility of obtaining
informed consent prospectively, the investigators
requested that neither retrospective patient consent nor
formal assent from relatives be required. The study proto-
col allowed for future measurements for retrospective
analyses. The complete study was performed in compli-
ance with the Helsinki Declaration. Both the prospective
study protocol and the retrospective analyses were
approved by the Central Oxford Research Ethics Commit-
tee and the need for informed consent was waived for
both the prospective collection and the retrospective anal-
yses.
Diagnostic criteria for VAP
VAP was suspected when a new or progressive infiltrate
was present along with at least two of the following signs
and symptoms: a) purulent respiratory secretions; b)
fever, defined as body temperature ≥38°C, or hypother-
mia defined as body temperature ≤35°C; and/or c) leuko-
cytosis defined as white blood cell count ≥10,000/mm3 or
leucopenia with total white blood cell count < 4500/mm3
or > 15% immature neutrophils (bands) regardless of
total peripheral white blood cell count. Diagnosis of VAP
had to be substantiated by positive culture results of
blindly obtained bronchoalveolar lavage fluid. Non-
directed bronchoalveolar lavage (NBL) fluid is routinely
obtained in the John Radcliffe hospital as part of micro-
biological surveillance [18]. If VAP was suspected antimi-
crobial treatment was started if warranted. However,
definite diagnosis of VAP was made retrospectively if the
clinical, radiological and microbiological data were
deemed consistent with a diagnosis of VAP by two inde-
pendent senior clinicians as described previously [19].BMC Pulmonary Medicine 2009, 9:49 http://www.biomedcentral.com/1471-2466/9/49
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Patients without infectious lung pathology by clinical and
radiological criteria who were intubated and mechani-
cally ventilated for at least 5 days served as a control
group.
Diagnostic criteria for ALI/ARDS
ALI/ARDS was diagnosed by the NAECC-criteria [5].
Data collection
Baseline characteristics (including age, gender, duration
of intubation and mechanical ventilation before study
enrolment, and prior antimicrobial therapy) and admis-
sion diagnosis were recorded for each patient. In addition,
respiratory parameters (tidal volume size, level of positive
end - expiratory pressure, levels of peak airway pressure)
and infectious parameters, as well as the multi-organ dys-
function score (MODS), the clinical pulmonary infection
score (CPIS) and lung injury score (LIS) were recorded
daily [20-23].
Sampling and processing
From the day of initiation of mechanical ventilation,
blood was collected in tubes coated with ethylenediamine
tetraacetic acid each alternate day. The tubes were centri-
fuged at 1500 × g for 10 minutes at 4°C. The supernatant
was collected and stored at -80°C.
Measurements
Levels of CC16 measured with an enzyme-linked immu-
nosorbent assay (ELISA). In short, 96 well plates were
coated with 25 ng monoclonal anti-human CC16 anti-
body AY1E6 (HyCult, Uden, The Netherlands). Calibrator
(Biovendor, Heidelberg, Germany) and samples were
diluted as appropriate and incubated for one hour. Then
the plates were washed and incubated for one hour with
10 ng polyclonal biotinylated anti-human CC16 detec-
tion antibody A0257 (Dako, Glostrup, Denmark). After
washing, streptavidin labeled with poly-horseradish per-
oxidase (Sanquin, Amsterdam, The Netherlands) was
added and incubated for 30 minutes. Finally, after three
washes, 100 μl sodium-acetate buffer (0.11 mol/L, pH
5.5) containing 100 μg/ml tetramethylbenzidine and
0.003% H2O2  was added and the color reaction was
stopped by 2 M H2SO4. The detection limit of the assay
was 10 pg/ml and the recovery of CC16 in plasma was 91-
98%. Levels of SP-D and sRAGE were measured as with an
ELISA as described previously [24]. Levels of KL-6 were
measured with an enzyme immunoassay (Sanko-Junyaku
Co., Ltd, Tokyo, Japan) according to the instructions of
the manufacturer. All measurements were made in dupli-
cate.
Statistical analysis
Results are expressed as means ± standard deviation (SD)
for normally distributed data or as medians with inter-
quartile ranges (IQR). To compare baseline differences
between control patients and VAP patients the Student's t
test was used or the Mann Whitney U test as appropriate.
Proportions were compared using the chi-square test with
Yates correction or Fisher's exact test when necessary.
Spearman's rho was used to determine the linear relation-
ship between plasma levels of biological markers and LIS.
To study changes over time in control patients and
patients developing VAP, serial data were analyzed using
linear mixed models. To compare differences between
control patients and VAP patients, the highest levels
observed in control patients were compared with the lev-
els observed on the day of diagnosis of VAP. Differences
between VAP patients with or without ALI/ARDS were
analyzed by adding presence of ALI/ARDS as a factor into
the linear mixed model.
As a next step we investigated the diagnostic accuracy of
plasma levels of the pulmonary proteins for the diagnosis
of ALI/ARDS in patients with VAP. In order to study
whether the protein levels were diagnostic of ALI/ARDS
we constructed receiver-operating characteristic (ROC)
curves with the values measured on the day of VAP diag-
nosis. Cut-off values were selected to calculate sensitivities
and specificities.
All analyses were performed using SPSS version 14.02
(Chicago, IL, USA). A p-value < 0.05 was considered statis-
tically significant.
Results
Patients
Thirty-seven patients were enrolled of which 22 patients
developed VAP. Fifteen patients did not develop VAP and
served as controls. VAP was diagnosed at median 6 [IQR
5-12] days after initiation of mechanical ventilation. Of
VAP patients, 10 patients developed ALI/ARDS at the time
of VAP diagnosis, or within 2 days. There were no control
patients who developed ALI/ARDS. Eight VAP patients
and 1 control patient died.
Baseline characteristics and admission diagnosis are pre-
sented in table 1. At study entry (i.e., prior to development
of VAP), the MODS, LIS and CPIS were higher in patients
who developed VAP as compared to control patients.
There were no differences between VAP patients who
developed ALI/ARDS and VAP patients who did not
develop VAP.
Ventilation data are shown in figure 1. Tidal volumes, lev-
els of PEEP and peak airway pressures at study enrollment
were comparable for VAP patients and control patients,
and did not change significantly over time. However, lev-
els of PEEP and peak airway pressures increased inBMC Pulmonary Medicine 2009, 9:49 http://www.biomedcentral.com/1471-2466/9/49
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patients who developed ALI/ARDS, and were significantly
higher after 2 days (p < 0.01 and p < 0.01).
Microbiology data are given in table 2. VAP was caused by
Gram-negative pathogens in 13 patients and by Gram-
positive pathogens in 9 patients. ALI/ARDS was diagnosed
in 7 patients with Gram-negative VAP and in 3 with Gram-
positive VAP (p = 0.34).
Plasma levels of pulmonary proteins with VAP
At study entry, plasma levels of all pulmonary proteins
were comparable between VAP patients and controls
(table 1), although there was a trend for a higher CC16
level in patients who developed VAP. Serial data are
shown in figure 2 and 3. Figure 2 shows plasma levels of
the smaller proteins CC16 and sRAGE, figure 3 shows
plasma levels of the larger proteins SP-D and KL-6. Over-
all, plasma levels of pulmonary proteins did not change
over time, neither in VAP patients nor in control patients.
Plasma levels of pulmonary proteins with ALI/ARDS
While plasma levels of CC16 and SP-D remained constant
in VAP patients who did not develop ALI/ARDS, plasma
levels of these pulmonary proteins increased in patients
who eventually developed ALI/ARDS. Patients with ALI/
ARDS had significantly higher plasma levels of CC16 and
SP-D (linear mixed models, P = 0.003 and p = 0.01 respec-
tively, figure 4). Plasma CC16 levels became significantly
different between the ALI/ARDS and the non-ALI/ARDS
group 2 days before diagnosis of VAP. No differences were
Table 1: Characteristics of the study population at study enrolment
Patients with VAP Patients without VAP 
(controls)
patients developing ALI/ARDS patients not developing ALI/
ARDS
(n = 10) (n = 12) (n = 15)
Age (yrs) 67 ± 17 64 ± 13 56 ± 14
Male gender (n, %) 7 (70%) 10 (83%) 8 (67%)
APACHE II-score 22.4 ± 6.7 23.7 ± 4.2 19.7 ± 9.6
MODS 10.8 ± 3.8 10.8 ± 3.0 7.2 ± 3.2*
LIS 1.9 ± 0.8 1.7 ± 1.0 1.1 ± 0.7
CPIS 5.5 ± 1.8 6.7 ± 1.4 4.9 ± 1.4*
Tidal volume (ml) 550 ± 90 585 ± 110 590 ± 130
Tidal volume per kg IBW (ml/kg) 6.6 ± 1.8 7.8 ± 1.6 7.7 ± 1.7
Smoking history 7 (70%) 5 (42%) 7 (47%)
Bronchial asthma 0 (0%) 1 (8%) 0 (0%)
CC16 (ng/ml) 30 [10 - 36] 14 [8.1 - 26] 6.5 [3.6 - 20]
sRAGE (pg/ml) 862 [245 - 1582] 830 [499 - 1527] 560 [350 - 847]
SP-D (ng/ml) 12 [3.7 - 28] 17 [5.1 - 32] 14 [10 - 23]
KL-6 (U/ml) 292 [183 - 495] 279 [161 - 470] 283 [164 - 377]
Admission diagnosis
Abdominal sepsis 1 2 3
Abdominal aortic aneurysm 1
Aspiration pneumonia 1 1
Cardiac arrest 0 2
Cardiac surgery 3 4 2
Intracranial hemorrhage 2
Meningitis 1 1
Near drowning 1
Fasciitis necroticans 3
Pancreatitis 1 2
Trauma 2 1 3
Abbreviations: APACHE, acute physiology and chronic health evaluation; MOD, multiple organ dysfunction; SOFA, sequential organ failure 
assessment; LIS, lung injury score; CPIS, clinical pulmonary infection score; IBW, ideal body weight; CC16, Clara cell protein; sRAGE, soluble 
receptor for advanced glycation end products; SP-D, surfactant protein D; *statistical significance (p < 0.05 in post-hoc analysis) of controls vs. VAP 
patients developing ALI/ARDS and vs. VAP patients not developing ALI/ARDS.BMC Pulmonary Medicine 2009, 9:49 http://www.biomedcentral.com/1471-2466/9/49
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found for plasma sRAGE and KL-6 levels, although there
was a trend for a difference in plasma KL-6 levels (p =
0.07).
Plasma CC16 levels correlated with the LIS (Spearman's
rho 0.32, p < 0.001). Plasma SP-D, KL-6 and sRAGE levels
showed no correlation with the LIS.
Receiver operating characteristic (ROC) curves
To determine the diagnostic accuracy of plasma levels of
these proteins for the diagnosis of ALI/ARDS we con-
structed ROC curves (figure 5). For this analysis, plasma
CC16 levels on the day of ALI/ARDS diagnosis were used
and compared to the highest levels observed in VAP
patients without ALI/ARDS. CC16 had excellent diagnos-
tic capacity as shown by an area under the curve (AUC) of
0.91 (95% confidence interval (CI) 0.79 - 1.00; p = 0.001;
Fig. 5). A level of 18 ng/ml or higher was diagnostic of
ALI/ARDS with a sensitivity of 80% and a specificity of
92%. This cut-off level yielded a sensitivity of 80% as one
ALI/ARDS patient had a plasma level of 9 ng/ml and one
ALI/ARDS patient had a plasma level of 14 ng/ml on the
day of diagnosis of ALI/ARDS.
As the number of Clara cells in the bronchioli and plasma
CC16 levels are chronically lowered in smokers and in
Respiratory data in VAP patients and control patients Figure 1
Respiratory data in VAP patients and control patients. Tidal volume (VT) per kilogram ideal body weight (IBW), posi-
tive end-expiratory pressure and peak airway pressure in patients developing ventilator-associated pneumonia (upper graphs) 
and control patients (lower graphs).
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Table 2: Isolated pathogens in patients with ventilator-associated pneumonia
Gram-positive Gram-negative
Escherichia coli 7
Pseudomonas aeruginosa 3
Methicillin-sensitive Staphylococcus aureus 2
Methicillin-resistant Staphylococcus aureus 5
Streptococcus pneumoniae 1
Enterococcus faecalis 1
Klebsiella pneumoniae 1
Morganella morganii 1
Haemophilus influenzae 1BMC Pulmonary Medicine 2009, 9:49 http://www.biomedcentral.com/1471-2466/9/49
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asthma patients [25,26], we analyzed whether ALI/ARDS
patients would be better identified by acute increases in
CC16 levels and not by absolute values. For this analysis
we considered an increase of 30% or more on the day of
ALI/ARDS diagnosis as positive. With this approach, only
one patient was falsely missed (sensitivity 90%) while the
specificity remained 92%. In our cohort, the positive pre-
dictive value was 90% and the negative predictive value
92%.
The AUC for SP-D was 0.80 (95% CI 0.58 - 1.00; p = 0.02).
None of the VAP patients without ALI/ARDS had a plasma
SP-D level of 50 ng/ml or higher (specificity 100%). How-
ever, with a cut-off level of 50 ng/ml only 7 patients with
ALI/ARDS were identified (sensitivity 70%). An approach
identifying ALI/ARDS patients by relative increases did
not yield better results (data not shown). The diagnostic
accuracy of KL-6 and sRAGE were low as shown by an
AUC of 0.71 (95% CI 0.40 - 1.00; p = 0.31) and 0.63 (95%
CI 0.37 - 0.90; p = 0.29).
Discussion
In current clinical practice, diagnosing ALI/ARDS remains
a major challenge. Recognizing patients with ALI/ARDS is
important so that management strategies such as lung-
protective mechanical ventilation using lower tidal vol-
umes and restrictive fluid strategies can be applied [3,27].
Moreover, while clinical studies on new therapies are per-
formed, specific therapies for ALI/ARDS may become
available in the near future [28]. In the present study we
found plasma CC16 levels to have a good diagnostic accu-
racy for the diagnosis of ALI/ARDS in patients with VAP.
Two clinical definitions are currently employed to diag-
nose ALI/ARDS in mechanically ventilated patients: the
NAECC definition [5] and the LIS as described by Murray
et al. [23]. A third definition, as defined by the Delphi cri-
teria has been developed recently [29]. One problem with
all three definitions is that they are subject to personal
interpretation [6]. Adding objective components to scor-
ing systems might increase their reliability. Many proteins
have been proposed as biological markers for ALI/ARDS.
A practical problem is, however, that many of these mark-
ers have to be measured in epithelial lining fluid or bron-
choalveolar lavage fluid which is difficult and laborious to
CC16 and sRAGE levels in VAP patients and control patients Figure 2
CC16 and sRAGE levels in VAP patients and control 
patients. Plasma levels of Clara cell protein (CC16) and sol-
uble receptor for advanced glycation end products (sRAGE) 
in patients who developed ventilator-associated pneumonia 
(left graphs) and mechanically ventilated control patients 
(right graphs). In the left graphs day 0 represents the day of 
ventilator-associated pneumonia diagnosis. In the right graphs 
day 0 represents the day of start of mechanical ventilation.
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SP-D and KL-6 levels in VAP patients and control patients Figure 3
SP-D and KL-6 levels in VAP patients and control 
patients. Plasma levels of surfactant protein D (SP-D) and 
Krebs von den Lungen (KL-6) in patients who developed ven-
tilator-associated pneumonia (left graphs) and mechanically 
ventilated control patients (right graphs).
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obtain. Blood samples can however be easily drawn from
indwelling catheters. Pulmonary proteins that leak to the
circulation in a pathophysiological way related to (devel-
opment of) ALI/ARDS, may serve as biological markers.
Previous experimental studies showed plasma CC16 lev-
els to rise in close relation to pulmonary injury [30-32].
To our best knowledge, no reports exist on the diagnostic
accuracy of these pulmonary proteins for the diagnosis
ALI/ARDS. The present study shows that plasma CC16
levels have excellent diagnostic accuracy and is superior to
plasma levels of SP-D, sRAGE and KL-6.
One problem with studying new biological markers is that
the measurement techniques used by different study
groups are not standardized. In most studies levels of
CC16 have been measured by a latex immunoassay while
for measuring levels of SP-D many different techniques
are employed. Prior to the study, we compared results
obtained by our ELISA with results from measurements
with the latex immunoassay described by Bernard et al.
[33]. On 80 samples, the correlation between both meas-
urement techniques was 0.70 and the 95% limits of agree-
ment were 1.6 ± 9.0 ng/ml (data not shown). Therefore,
our results can be compared with data from studies that
used the latex immunoassay. Due to a different ELISA
technique, the absolute levels of SP-D from our study can-
not be directly compared with levels observed in other
studies. However, the recovery of our SP-D assay was 95
to 105%, from which we conclude that we truly measured
SP-D.
As the clinical assessment of both ALI/ARDS [6] and VAP
[34] are hampered by the lack of a gold standard the sen-
sitivity and specificity of any scoring system is moderate at
best. Despite these limitations, we observed a good diag-
nostic accuracy for plasma CC16 levels for the presence of
ALI/ARDS. Furthermore, our results show an increase in
plasma CC16 levels even before ALI/ARDS is diagnosed.
Therefore, we speculate that increases in plasma CC16 lev-
els may inform physicians on development of ALI/ARDS.
Rising plasma CC16 levels may allow for early adjust-
ments of ventilator settings or additional therapies. This,
however, needs to be confirmed in prospective studies.
Studies in human volunteers have shown plasma CC16
levels to increase in settings of subtle sub-clinical lung
injury [30,32]. This has been ascribed to the fact that
Biomarker levels in VAP patients with and without ALI/ARDS Figure 4
Biomarker levels in VAP patients with and without 
ALI/ARDS. Plasma levels of CC16, sRAGE, SP-D and KL-6 
in patients developing ventilator-associated pneumonia. Open 
circles: patients without ALI/ARDS after onset of ventilator-
associated pneumonia, closed circles: patients who pro-
gressed to ALI/ARDS at or after onset of ventilator-associ-
ated pneumonia.
-4 -2 0 2 4 6 8
0
20
40
60
Days
C
C
1
6
 
(
n
g
/
m
l
)
-4 -2 0 2 4 6 8
0
25
50
75
100
Days
S
P
-
D
 
(
n
g
/
m
l
)
-4 -2 0 2 4 6 8
0
500
1000
1500
2000
Days
R
A
G
E
 
(
p
g
/
m
l
)
-4 -2 0 2 4 6 8
0
250
500
750
1000
Days
K
L
-
6
 
(
U
/
m
l
)
ROC curves Figure 5
ROC curves. Receiver operating characteristic curves of 
CC16, sRAGE, SP-D and KL-6 for the diagnosis of ALI/ARDS 
on the day patients developed ventilator-associated pneumo-
nia. AUC area under the curve.
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CC16 is a small protein that may leak across the alveolo-
capillary barrier more easily than larger proteins like SP-D
and KL-6. As VAP is characterized by intense pulmonary
inflammation, we expected the plasma CC16 levels to be
lower in ventilated controls as compared to VAP-patients.
Our results point out, however, that plasma CC16 levels
in VAP-patients are comparable to those in ventilated
patients without VAP. However, most of the control
patients in our study had one or more risk factors for ALI/
ARDS raising the possibility that these patients were simi-
lar from a pathophysiological point of view. Indeed, sep-
sis, trauma, pancreatitis and fasciitis may evoke low grade
lung injury which may explain the comparable plasma
CC16 levels between patients with VAP and patients with-
out VAP.
Moreover, mechanical ventilation and pulmonary infec-
tion may have comparable effects on leakage of CC16. We
previously showed plasma CC16 levels to increase with
mechanical ventilation [24]. In that study, patients sub-
jected to low tidal volumes and PEEP and patients sub-
jected to high tidal volumes without PEEP had
comparable levels of PEEP resulting in equal levels of pul-
monary stretch, and therefore maybe comparable CC16
levels. Animal studies have shown CC16 levels to increase
when levels of PEEP or tidal volumes are increased [35].
As tidal volumes in the present study were comparable
between patients with and without ALI/ARDS. The higher
levels of PEEP in the ALI/ARDS group may have contrib-
uted to the sustained increase of plasma CC16 levels.
In patients with ALI/ARDS plasma CC16 levels were three
times higher as compared to patients without ALI/ARDS.
Furthermore, CC16 levels correlated with the LIS. This is
in line with the results of others who found the highest
CC16 levels in non-survivors of ALI/ARDS [16]. Patients
with the highest grade of lung injury may thus have the
highest plasma CC16 levels.
We did not find a strong relation between plasma levels of
sRAGE and the development of ALI/ARDS. This is in con-
trast to earlier reports on elevated sRAGE levels in both
epithelial lining fluid or bronchoalveolar lavage fluid and
plasma of patients with ALI/ARDS [9,36]. Plasma levels of
sRAGE may also be influenced by other factors than lung
injury as membrane-bound RAGE is also expressed by the
endothelium in the circulation [37]. Moreover, different
isoforms of sRAGE have been described and different
ELISA techniques may detect different isoforms [9]. We
used however the same technique as described by investi-
gators who found a non-significant increase in sRAGE in
bronchoalveolar lavage fluid of ALI/ARDS patients [36].
In their analysis, however, sRAGE levels from ALI/ARDS
patients were compared with healthy controls, and not
intubated and mechanically ventilated patients as in our
study. This may have accounted for our negative findings.
Conclusion
Plasma CC16 seems a promising biological marker for
ALI/ARDS in patients with VAP. However, before using
CC16 as a biological marker for ARDS in VAP, our results
need confirmation in larger study populations. Future
studies should investigate new scoring systems for ALI/
ARDS using biomarkers levels, including levels of CC16.
Finally, as the ventilator settings have become more and
more important in patient care, studies that investigate
the effect of different ventilator strategies on plasma CC16
levels are also warranted.
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